A-PRF and CGF in Palatal Donor Site Healing (FGG)

Effects on Patients' Postoperative Morbidity and Donor Site Wound Healing of A-PRF and CGF Application After Free Gingival Graft Harvesting: A Comparative Randomized Clinical Trial

The objective of this study was to compare and evaluate the effects of concentrated growth factor (CGF) and advanced platelet-rich fibrin (A-PRF) clot membranes on palatal epithelial wound healing and postoperative discomfort following free gingival graft (FGG) harvesting.

Study Overview

• Status: Completed
• Conditions: Free Gingival Graft
• Intervention / Treatment: Procedure: Advanced platelet-rich fibrin; Procedure: Concentrated growth factor; Procedure: Sterile gelatin sponge

Detailed Description

The objective of this study was to compare and evaluate the effects of concentrated growth factor (CGF) and advanced platelet-rich fibrin (A-PRF) clot membranes on palatal epithelial wound healing and postoperative discomfort following free gingival graft (FGG) harvesting.

Fourty-five patients who underwent FGG harvesting were randomly assigned to three groups: (1) control group (n=15), receiving only a sterile gelatin sponge; (2) A-PRF group (n=15), receiving A-PRF clot membranes; and (3) CGF group (n=15), receiving CGF clot membranes at the donor site. The epithelization rate, color match, and sensation scores of the palatal wound were assessed at 1, 2, 3, and 4 weeks postoperatively. Pain levels, analgesic consumption, and bleeding time were self-reported by patients for the first 7 days of healing.

• Study Type: Interventional
• Enrollment (Actual): 45
• Phase: Phase 2

Contacts and Locations

Study Locations

• Turkey (Türkiye)
  • Ordu, Turkey (Türkiye), 52100
    • Ordu University

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• at least 18 years old,
• without systemic or periodontal diseases,
• without medical contraindications to periodontal surgery
• with full-mouth plaque control scores ≤ 20%
• Gingival index scores ≤ 1

Exclusion Criteria:

• smoking habits,
• diabetes mellitus,
• pregnancy or lactation,
• removable upper denture,
• regular medication that could interpose the healing process, undergoing bisphosphonate therapy, history of radiation therapy of the jaws, and follow-up consults

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Single

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Advanced platelet-rich fibrin; Advanced platelet-rich fibrin clot membranes on palatal epithelial wound after harvesting free gingival graft	Procedure: Advanced platelet-rich fibrin; Advanced platelet-rich fibrin membranes and free gingival graft
Active Comparator: Concentrated growth factor; Concentrated growth factor clot membranes on palatal epithelial wound after harvesting free gingival graft	Procedure: Concentrated growth factor; Concentrated growth factor membranes and free gingival graft
Placebo Comparator: Sterile gelatin sponge; Sterile gelatin sponge on palatal epithelial wound after harvesting free gingival graft	Procedure: Sterile gelatin sponge; Sterile gelatin sponge and free gingival graft

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Epithelialization	Rate of re-epithelialization with re-total, partial, or none by dropping hydrogen peroxide (3%) on the wound surface	Baseline
Epithelialization	Rate of re-epithelialization with re-total, partial, or none by dropping hydrogen peroxide (3%) on the wound surface	1 week post-surgery
Epithelialization	Rate of re-epithelialization with re-total, partial, or none by dropping hydrogen peroxide (3%) on the wound surface	2 week post-surgery
Epithelialization	Rate of re-epithelialization with re-total, partial, or none by dropping hydrogen peroxide (3%) on the wound surface	3 week post-surgery
Epithelialization	Rate of re-epithelialization with re-total, partial, or none by dropping hydrogen peroxide (3%) on the wound surface	4 week post-surgery
Pain perception	Presence of pain perception on the Visual Analog Scale (VAS) pain scores (0: no pain, 1: minimal pain, 10: severe pain)	Baseline
Pain perception	Presence of pain perception on the Visual Analog Scale (VAS) pain scores (0: no pain, 1: minimal pain, 10: severe pain)	1st day after surgery
Pain perception	Presence of pain perception on the Visual Analog Scale (VAS) pain scores (0: no pain, 1: minimal pain, 10: severe pain)	2nd day after surgery
Pain perception	Presence of pain perception on the Visual Analog Scale (VAS) pain scores (0: no pain, 1: minimal pain, 10: severe pain)	3th day after surgery
Pain perception	Presence of pain perception on the Visual Analog Scale (VAS) pain scores (0: no pain, 1: minimal pain, 10: severe pain)	4th day after surgery
Pain perception	Presence of pain perception on the Visual Analog Scale (VAS) pain scores (0: no pain, 1: minimal pain, 10: severe pain)	5th day after surgery
Pain perception	Presence of pain perception on the Visual Analog Scale (VAS) pain scores (0: no pain, 1: minimal pain, 10: severe pain)	6th day after surgery
Pain perception	Presence of pain perception on the Visual Analog Scale (VAS) pain scores (0: no pain, 1: minimal pain, 10: severe pain)	7th day after surgery
Pain perception	Presence of pain perception on the Visual Analog Scale (VAS) pain scores (0: no pain, 1: minimal pain, 10: severe pain)	14th day after surgery
Pain perception	Presence of pain perception on the Visual Analog Scale (VAS) pain scores (0: no pain, 1: minimal pain, 10: severe pain)	21st day after surgery
Pain perception	Presence of pain perception on the Visual Analog Scale (VAS) pain scores (0: no pain, 1: minimal pain, 10: severe pain)	28th day after surgery

Collaborators and Investigators

• Sponsor: Ordu University
• Investigators: Principal Investigator: Figen Öngöz Dede, Prof, Ordu Universitesi

Study record dates

Study Major Dates

• Study Start (Actual): November 1, 2020
• Primary Completion (Actual): May 30, 2022
• Study Completion (Actual): May 31, 2022

Study Registration Dates

• First Submitted: February 10, 2026
• First Submitted That Met QC Criteria: February 26, 2026
• First Posted (Actual): February 27, 2026

Study Record Updates

• Last Update Posted (Actual): February 27, 2026
• Last Update Submitted That Met QC Criteria: February 26, 2026
• Last Verified: February 1, 2026

More Information

Terms related to this study

• Keywords: Advanced Platelet-Rich Fibrin; Concentrated Growth Factor
• Other Study ID Numbers: 2020\159

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No